Clinical Research Directory

Browse clinical research sites, groups, and studies.

Sites Groups Studies

Back to Studies

ACTIVE NOT RECRUITING

NCT07895563

A Study to Evaluate the Effects of a Dietary Supplement on Weight Management and Appetite Control

Sponsor: MNnutra

View on ClinicalTrials.gov

Summary

This is a randomized, double-blind, placebo-controlled, decentralized clinical trial evaluating the effects of MN Nutra GeLiPthin-1™, a multi-ingredient dietary supplement, on body weight, BMI, waist circumference, appetite, satiety, and energy levels in overweight and obese adults over six weeks. A total of 170 generally healthy adults aged 18-65 years with a BMI of 27.0-35.0 kg/m² will be randomized 1:1 to receive either the active supplement or a matching placebo. Participants will take three capsules orally twice daily for six weeks. All study activities are conducted remotely, including electronic consent, self-administered anthropometric measurements using a sponsor-provided Withings Scale and tape measure, and weekly online questionnaires via the Citruslabs digital study platform. The primary outcome is change in body weight from Baseline to Week 6.

Key Details

Gender

All

Age Range

18 Years - 65 Years

Study Type

INTERVENTIONAL

Enrollment

170

Start Date

2026-08-27

Completion Date

2026-10

Last Updated

2026-10-26

Healthy Volunteers

Yes

Conditions

Overweight Obesity Weight Management Appetite Control

Interventions

DIETARY_SUPPLEMENT

MN Nutra GeLiPthin-1™ Dietary Supplement

Participants will take three capsules orally twice daily for six weeks. All study activities are conducted remotely, including electronic consent, self-administered anthropometric measurements using a sponsor-provided Withings Scale and tape measure, and weekly online questionnaires via the Citruslabs digital study platform.

DIETARY_SUPPLEMENT

Placebo

Participants receive matching placebo capsules containing microcrystalline cellulose (quantity sufficient to match active fill weight of 1920 mg per dose)

Inclusion Criteria: * Male or female. * Aged 18 to 65 years. * Anyone currently experiencing issues regarding all of the following: healthy weight management * appetite management and/or food cravings * energy levels. * Resides in the United States. * Body Mass Index (BMI) ≥ 27.0 and \< 35.0 kg/m². * Anyone who is generally healthy - does not live with any uncontrolled chronic disease. * Willing to follow the study protocol. * Willing to maintain current diet, physical activity, and lifestyle habits for the study duration. * Willing to abstain from alcohol consumption during the study period. Exclusion Criteria: * Current use or use within three months of GLP-1 receptor agonists (e.g., semaglutide/Ozempic/Wegovy, liraglutide/Saxenda/Victoza, tirzepatide/Mounjaro/Zepbound, or dulaglutide/Trulicity) or any prescription weight-loss medication. * Concurrent use of overlapping weight-management dietary supplements that participants are unwilling to discontinue for the study duration. * Anyone with pre-existing chronic conditions that would prevent participants from adhering to the protocol, including oncological and psychiatric disorders. * Anyone who is currently undergoing treatment for cancer, or has had a serious illness requiring hospitalization in the last 3 months. * Currently undergoing or planning to undergo any significant medical procedures in the next six weeks. * Currently enrolled in a medically supervised weight-loss program, or has a history of bariatric surgery within the past 12 months. * Any women who are pregnant, breastfeeding, or trying to conceive (or who will be at any point during the study period). * Heavy drinkers or drug users. * A heavy drinker is considered to be a woman who drinks 8 or more alcoholic drinks per week or a man who drinks 15 or more alcoholic drinks per week. * Active or historical eating disorder (e.g., anorexia nervosa, bulimia nervosa, binge eating disorder). * Known allergy or hypersensitivity to any ingredient in the study product or placebo. * Diagnosed diabetes (type 1 or type 2) or use of insulin or antidiabetic medications (e.g., metformin). * Known cardiovascular disease or uncontrolled hypertension. * Clinically significant liver disease or known abnormal liver function. * Currently testing, or planning to in the next six weeks, a product for another research study.

Locations (1)

Citruslabs

Las Vegas, Nevada, United States